INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα
Retrieved on:
星期一, 十月 30, 2023
Neoplasm, PD-L1, Trastuzumab, AD, Therapy, TNF, Macrophage, CD47, Research, Poster, Society for Immunotherapy of Cancer, CD8, Mouse, LAG3, Disease, Breast cancer, ADCP, Microglia, Brain, Tumor microenvironment, Phagocytosis, Safety, DMD, Cancer, Remyelination, Instituto de Biología y Medicina Experimental, Society, TME, MS, Vaccine, Medical imaging, Immunotherapy
Boca Raton, Florida, Oct. 30, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative inhibitor of soluble TNF in the treatment of high-risk MUC4 expressing HER2+ breast cancer. Roxana Schillaci Ph.D. of Instituto de Biología y Medicina Experimental in Buenos Aries, Argentina, will present her work at the 38th annual Society of Immunotherapy in San Diego, California which runs from November 1-4.
Key Points:
- INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular phagocytosis (ADCP).
- The poster entitled “INB03: a new immune checkpoint inhibitor that reprograms polarization and promotes ADCP in human macrophages,” shows that INB03 is an innate immune checkpoint inhibitor working through the SIRPα-CD47 pathway to promote ADCP.
- INB03 downregulates SIRPα expression to eliminate the “don’t eat me signal” and promote ADCP.
- INB03 neutralizes sTNF, repolarizing tumor protecting M2 macrophages to M1 anti-tumor macrophages, enhances ADCP with trastuzumab, and reduces SIRPα expression.